The Federal Circuit vacated a district court’s indefiniteness finding for a viscometer patent, holding that the intrinsic record — not dictionary definitions — governs claim construction, and that terms of degree are not indefinite when the specification provides adequate context for a skilled
The Federal Circuit granted mandamus, holding that a foreign defendant cannot defeat Rule 4(k)(2) personal jurisdiction in the plaintiff’s chosen forum by unilaterally consenting to jurisdiction in a different district after the lawsuit is filed.
The Federal Circuit affirmed that Sandoz’s generic pirfenidone label would not induce infringement of Genentech’s method-of-treatment patents, and also upheld invalidity of the liver function test patents as obvious, clarifying the inducement standard for drug labels in Hatch-Waxman litigation.
The Federal Circuit reversed a summary judgment of patent invalidity for anticipation, finding genuine disputes about whether the alleged prior art product predated the patent’s critical date, and separately affirmed that Mosaic’s claimed trade dress was invalid as functional.
The Federal Circuit held that genuine disputes of material fact precluded summary judgment of patent invalidity for failure to name a co-inventor, reversing the district court’s ruling that the patents were invalid for nonjoinder.
The Federal Circuit held that collateral estoppel from a prior IPR proceeding can invalidate claims in a later IPR even when the claims use different language, as long as the differences do not materially alter the question of patentability.
The Federal Circuit upheld the exclusion of a patent owner’s expert witness whose infringement opinion rested on a claim construction that materially differed from the district court’s adopted construction, resulting in summary judgment of noninfringement.
The Federal Circuit held that a patent owner’s disclaimer made for the first time during an IPR proceeding does not bind the PTAB in that same proceeding, preventing patentees from narrowing claim scope through argument alone to avoid invalidity.
The Federal Circuit held that the Patent Trial and Appeal Board may adopt claim constructions that differ from those entered by a district court in concurrent litigation, as the two proceedings are legally independent.
The Federal Circuit unanimously affirmed the district court’s holding that five patent claims covering ibrutinib (Imbruvica) — a breakthrough cancer drug — were not invalid for obviousness, lack of written description, or lack of enablement, underscoring appellate deference to trial court fact